查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2059093

藥物基因體學市場預測至2034年－按產品類型、技術、檢體類型、服務類型、應用、最終用戶和地區分類的全球分析

Pharmacogenomics Market Forecasts to 2034 - Global Analysis By Product (Instruments, Reagents & Consumables, and Software & Bioinformatics Tools), Technology, Sample Type, Service Type, Application, End User and By Geography
出版日期: | 出版商: Stratistics Market Research Consulting | 英文 | 商品交期: 2-3個工作天內

價格

根據 Stratistics MRC 的數據，全球藥物基因體學市場預計將在 2026 年達到 93 億美元，到 2034 年達到 286 億美元，在預測期內以 15.0% 的複合年成長率成長。

藥物基因體學是一門研究個別基因組成如何影響其對藥物反應的科學，涵蓋藥物代謝、個體療效差異以及副作用易感性。透過分析編碼藥物代謝酶、轉運蛋白和目標受體的基因突變，藥物基因體學檢測能夠幫助臨床醫生實現藥物選擇的個人化和劑量調整，從而最大限度地提高療效並最大限度地減少不良反應。藥物藥物基因體學已融入精準醫療的框架，涵蓋腫瘤學、精神病學、循環系統和感染疾病等領域，並正在重塑全球藥物開發平臺、臨床實踐指南和病患安全規程。

精準醫療架構及個人化醫療在所有臨床專科的推廣

全球醫療保健系統正從基於人群平均水平的治療方案轉向基於基因生物標記數據的個人化治療策略，這極大地推動了對藥物基因體學檢測服務和平台的需求。臨床證據表明，基於藥物基因體學組學的處方能夠減少藥物不良反應、提高藥物療效並降低總治療成本，這強烈促使醫療保健系統的處方集委員會和臨床領導者將基因檢測納入標準藥物管理流程。腫瘤科、精神科和循環系統主導了這一趨勢，並且在基層醫療也日益普及。隨著臨床效用證據在更廣泛的治療領域不斷積累，藥物基因體學正成為實現個人化醫療的基礎要素。

保險報銷不足限制了大規模臨床應用。

儘管越來越多的臨床證據支持基於藥物基因體學的處方指導，但公共和私人保險公司的報銷仍然不穩定，且往往不足以涵蓋全面的基因組檢測費用。在許多市場，報銷僅限於特定的、證據充分的臨床場景，這使得在常規門診環境中廣泛應用藥物基因組學在經濟上面臨挑戰。由於缺乏保險公司可以統一應用於所有藥物基因體學適應症的標準化臨床效用框架，保險覆蓋範圍的評估過程被延長。如果沒有更廣泛且可預測的保險報銷，醫療系統投資藥物基因體學基礎設施和臨床工作流程的經濟理由仍然有限，這限制了藥物基因組學在專業大學醫院之外的應用。

藥物基因體學成果整合到電子健康記錄和臨床決策支援工具中。

將藥物基因體學檢測結果直接整合到電子健康記錄平台和臨床決策支援介面中，為在臨床實踐中實現精準用藥提供了突破性的機會。當與藥物選擇相關的基因變異自動顯示在藥物處方流程旁邊時，臨床醫生無需接受專門的藥物基因體學培訓，即可根據藥物基因組學指導進行用藥。醫療資訊技術供應商正積極將藥物基因體學內容模組整合到其平台中，實驗室也正在開發與電子健康記錄系統整合的報告流程。這種臨床工作流程的整合有望顯著加速藥物基因體學學向常規處方實踐的轉化，從而在多個治療領域帶來顯著的市場成長。

圍繞人口層面遺傳資料儲存庫的倫理問題與資料管治挑戰

檢測實驗室、生物樣本庫和製藥公司累積的大規模藥物基因體學資料集引發了許多重要的倫理問題，包括基因資料的所有權、二次研究中的知情同意，以及雇主和保險公司可能歧視性地濫用基因資訊。在許多司法管轄區，基因數據監管框架仍不完善，這給了建構藥物基因體學數據平台的機構合規的不確定性。圍繞基因數據隱私的高調爭議加劇了消費者的擔憂，並提高了基因數據管治的政治重要性，這可能會阻礙大規模人群篩檢計畫的實施，而這些計畫本可以最有效地展現藥物基因體學的臨床和經濟價值。

新冠疫情的影響：

新冠疫情凸顯了藥物基因體學的重要性，它不僅是理解患者對抗病毒療法反應差異的關鍵工具，也是識別重症高風險族群的重要手段。疫情期間，快速最佳化治療方案的迫切需求加速了人們對藥物基因體學在感染疾病管理中應用的關注。疫情過後，藥物基因體學的應用範圍從腫瘤學擴展到感染疾病、免疫學和疫苗反應研究等領域，從而擴大了其潛在市場。此外，疫情也促進了全球基因組數據基礎設施的投資，建構了一個更廣泛的平台，使藥物基因體學應用能夠從中提取分析能力和臨床有效性證據。

在預測期內，耗材細分市場預計將佔據最大的市場佔有率。

在預測期內，耗材領域預計將佔據最大的市場佔有率。這反映了持續的基因檢測業務需要定期且大量採購試劑、定序盒、基因型鑒定晶片和檢體採集材料。與一次性資本投資的設備不同，耗材能夠產生可預測且持續的收入流，其收入與檢測量的成長成正比。隨著參考實驗室、醫院檢測項目和直接面對消費者 (DTC) 平台開展的藥物基因體學檢測數量不斷增加，對耗材的需求也將相應成長。高利潤的耗材模式也對希望在其現有檢測平台基礎設施中建立永續的、以銷售為導向的收入流的設備製造商具有吸引力。

在預測期內，次世代定序(NGS) 領域預計將呈現最高的複合年成長率。

在預測期內，受定序成本持續下降和臨床對綜合多基因藥物基因體學組學檢測需求不斷成長的推動，次世代定序(NGS) 領域預計將呈現最高的成長率。 NGS 能夠在單次檢測中同時分析數百種與藥物基因體學相關的基因變異，與傳統的單基因檢測方法相比，能夠提供更高密度的臨床資訊。隨著 NGS 在標靶基因分型檢測方面成本競爭力的提升，臨床檢查室正在加速轉型為定序的藥物基因體學工作流程。更多基於 NGS 的藥物基因體學檢測方案獲得監管部門批准，正在加速其在腫瘤學及其他更廣泛治療領域的商業性化應用。

市佔率最大的地區：

在預測期內，北美預計將佔據最大的市場佔有率。這得歸功於美國世界一流的精準醫療研究基礎設施、先進的法規環境以及高度集中的、優先考慮基因組分析的製藥和生物技術公司。聯邦政府透過「全民研究計畫」（All of Us Research Program）等舉措進行的投資，正在建構大規模的藥物基因組學資料集，為臨床證據的產生提供支持。此外，美國擁有大多數提供全面藥物基因體學檢測服務的領先實驗室，以及包括臨床藥物資訊中心（CPIC）在內的臨床指南制定機構，這些機構正在製定循證處方框架，並在全國範圍內推動臨床應用。

複合年成長率最高的地區：

在預測期內，亞太地區預計將呈現最高的複合年成長率。這主要得益於中國、日本、韓國和澳洲政府主導的精準醫療項目，以及該地區大規模的人口基數和豐富的遺傳多樣性，為藥物基因組學研究提供了豐富的資源。中國國內基因組學產業的領導者正在迅速擴展其臨床級定序能力，從而降低檢測成本並提高藥物基因組學研究的可及性。隨著臨床醫生和患者對基因處方箋益處的認知不斷提高，以及亞洲特定患者群體中越來越多的證據支持，全部區域的基因檢測量正在激增。

主要公司：

藥物基因體學市場的主要參與者包括 Thermo Fisher Scientific、Illumina、QIAGEN、F. Hoffmann-La Roche、Agilent Technologies、Abbott Laboratories、Bio-Rad Laboratories、Danaher Corporation、Myread Genetics、Eurofins Scientific、Pacific Biosciences、LabSO、AIT Holdings、ANET、

免費客製化服務：

所有購買此報告的客戶均可享受以下免費自訂選項之一：

  • 企業概況
    • 對其他市場參與者（最多 3 家公司）進行全面分析
    • 對主要公司進行SWOT分析（最多3家公司）
  • 區域細分
    • 應客戶要求，我們提供主要國家的市場估算和預測，以及複合年成長率（註：需進行可行性檢查）。
  • 競爭性標竿分析
    • 根據產品系列、地理覆蓋範圍和策略聯盟對領先公司進行基準分析。

目錄

第1章執行摘要

  • 市場概覽及主要亮點
  • 促進因素、挑戰與機遇
  • 競爭格局概述
  • 戰略洞察與建議

第2章：研究框架

  • 研究目標和範圍
  • 相關人員分析
  • 研究假設和限制
  • 調查方法

第3章 市場動態與趨勢分析

  • 市場定義與結構
  • 主要市場促進因素
  • 市場限制與挑戰
  • 投資成長機會和重點領域
  • 產業威脅與風險評估
  • 技術與創新展望
  • 新興市場/高成長市場
  • 監管和政策環境
  • 新冠疫情的影響及復甦前景

第4章：競爭環境與策略評估

  • 波特五力分析
    • 供應商的議價能力
    • 買方的議價能力
    • 替代品的威脅
    • 新進入者的威脅
    • 競爭公司之間的競爭
  • 主要公司市佔率分析
  • 產品基準評效和效能比較

第5章 全球藥物基因體學市場：依產品分類

  • 裝置
    • 定序設備
    • PCR系統
    • 微陣列系統
    • 質譜儀
  • 試劑和耗材
    • 檢測試劑盒
    • 基因型鑒定盒
    • PCR試劑
    • 樣品製備試劑盒
    • 耗材定序
  • 軟體和生物資訊學工具
    • 臨床決策支援軟體
    • 數據分析軟體
    • 實驗室資訊管理系統（LIMS）

第6章 全球藥物基因體學市場：依技術分類

  • 聚合酵素鏈鎖反應（PCR）
    • 標準PCR
    • 即時PCR
    • 數位PCR
  • DNA定序
    • 次世代定序（NGS）
    • 桑格定序
  • 微陣列
  • 質譜分析
  • 電泳
  • 原位雜合反應
  • 其他技術

第7章：全球藥物基因體學市場：依樣本類型分類

  • 血液樣本
  • 唾液樣本
  • 口腔黏膜拭子
  • 組織樣本
  • 其他檢體類型

第8章 全球藥物基因體學市場：依服務類型分類

  • 藥物基因體學學檢測服務
  • 諮詢服務
  • 數據解讀服務

第9章 全球藥物基因體學市場：依應用分類

  • 腫瘤學
  • 心血管疾病
  • 神經病學和精神病學
  • 感染疾病
  • 疼痛管理
  • 罕見疾病
  • 藥物發現與開發
  • 個人化醫療
  • 其他用途

第10章 全球藥物基因體學市場：依最終用戶分類

  • 醫院和診所
  • 診斷檢查室
  • 學術研究機構
  • 製藥和生物技術公司
  • 受託研究機構（CRO）
  • 其他最終用戶

第11章 全球藥物基因體學市場：按地區分類

  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 英國
    • 德國
    • 法國
    • 義大利
    • 西班牙
    • 荷蘭
    • 比利時
    • 瑞典
    • 瑞士
    • 波蘭
    • 其他歐洲國家
  • 亞太地區
    • 中國
    • 日本
    • 印度
    • 韓國
    • 澳洲
    • 印尼
    • 泰國
    • 馬來西亞
    • 新加坡
    • 越南
    • 其他亞太國家
  • 南美洲
    • 巴西
    • 阿根廷
    • 哥倫比亞
    • 智利
    • 秘魯
    • 其他南美國家
  • 世界其他地區（RoW）
    • 中東
      • 沙烏地阿拉伯
      • 阿拉伯聯合大公國
      • 卡達
      • 以色列
      • 其他中東國家
    • 非洲
      • 南非
      • 埃及
      • 摩洛哥
      • 其他非洲國家

第12章 策略市場資訊

  • 工業價值網路和供應鏈評估
  • 空白區域和機會地圖
  • 產品演進與市場生命週期分析
  • 通路、經銷商和打入市場策略的評估

第13章 產業趨勢與策略舉措

  • 併購
  • 夥伴關係、聯盟和合資企業
  • 新產品發布和認證
  • 擴大生產能力和投資
  • 其他策略舉措

第14章：公司簡介

  • Thermo Fisher Scientific
  • Illumina
  • QIAGEN
  • F. Hoffmann-La Roche Ltd.
  • Agilent Technologies
  • Abbott Laboratories
  • Bio-Rad Laboratories
  • Danaher Corporation
  • Myriad Genetics
  • Eurofins Scientific
  • Pacific Biosciences
  • Laboratory Corporation of America Holdings
  • BD
  • SOPHiA GENETICS
  • Takara Bio Inc.
Product Code: SMRC36605

According to Stratistics MRC, the Global Pharmacogenomics Market is accounted for $9.3 billion in 2026 and is expected to reach $28.6 billion by 2034, growing at a CAGR of 15.0% during the forecast period. Pharmacogenomics is the scientific discipline that examines how an individual's genetic makeup influences their response to pharmaceutical agents, encompassing drug metabolism, efficacy variability, and adverse reaction susceptibility. By analyzing genetic variants in genes encoding drug-metabolizing enzymes, transporters, and target receptors, pharmacogenomic testing enables clinicians to personalize medication selection and dosing to maximize therapeutic benefit and minimize harmful effects. Integrated into precision medicine frameworks across oncology, psychiatry, cardiology, and infectious disease, pharmacogenomics is reshaping drug development pipelines, clinical practice guidelines, and patient safety protocols globally.

Market Dynamics:

Driver:

Rising adoption of precision medicine frameworks and personalized therapeutics across clinical specialties

Healthcare systems worldwide are transitioning from population-average treatment protocols to individualized therapeutic strategies informed by genetic biomarker data, driving substantial demand for pharmacogenomic testing services and platforms. Clinical evidence demonstrating reduced adverse drug reactions, improved medication efficacy, and lower overall treatment costs associated with pharmacogenomics-guided prescribing is compelling health system formulary committees and clinical leadership to integrate genetic testing into standard medication management pathways. Oncology, psychiatry, and cardiology are leading adoption, with growing penetration in primary care. As clinical utility evidence accumulates across broader therapeutic areas, pharmacogenomics is becoming a foundational component of personalized care delivery.

Restraint:

Inadequate reimbursement coverage limiting clinical integration at population scale

Despite growing clinical evidence supporting pharmacogenomic-guided prescribing, reimbursement coverage by public and private payers remains inconsistent and frequently insufficient to cover the cost of comprehensive genetic panel testing. In many markets, coverage is limited to specific high-evidence clinical scenarios, leaving broad clinical integration economically unviable for routine outpatient care. The absence of standardized clinical utility frameworks that payers can apply consistently across pharmacogenomic indications prolongs coverage evaluation processes. Without expanded and predictable reimbursement, the economic case for health systems to invest in pharmacogenomics infrastructure and clinical workflows remains constrained, limiting adoption beyond specialist academic medical center environments.

Opportunity:

Integration of pharmacogenomic insights into electronic health records and clinical decision support tools

The embedding of pharmacogenomic test results directly within electronic health record platforms and clinical decision support interfaces represents a transformative opportunity to operationalize precision prescribing at the point of care. When genetic variants relevant to drug selection are surfaced automatically alongside medication ordering workflows, clinicians can act on pharmacogenomic guidance without requiring specialized genetics training. Health IT vendors are actively building pharmacogenomics content modules into their platforms, and reference laboratories are developing EHR-integrated reporting pipelines. This clinical workflow integration is expected to dramatically accelerate the translation of pharmacogenomic science into routine prescribing practice, unlocking substantial market growth across multiple therapeutic areas.

Threat:

Ethical concerns and data governance challenges surrounding population-level genetic data repositories

The accumulation of large pharmacogenomic datasets by reference laboratories, biobanks, and pharmaceutical companies raises significant ethical questions regarding genetic data ownership, secondary research use consent, and the potential for discriminatory misuse of genetic information by employers or insurers. Regulatory frameworks governing genetic data are still evolving in many jurisdictions, creating compliance uncertainty for organizations building pharmacogenomics data platforms. High-profile controversies around genetic data privacy have heightened consumer sensitivity and increased the political salience of genetic data governance, potentially impeding the broad population screening programs that would most effectively demonstrate pharmacogenomics' clinical and economic value.

Covid-19 Impact:

COVID-19 highlighted pharmacogenomics as a critical tool for understanding differential patient responses to antiviral therapeutics and identifying populations at heightened risk of severe disease outcomes. The urgent need for rapid therapeutic optimization during the pandemic accelerated interest in pharmacogenomic applications within infectious disease management. Post-pandemic, the diversification of pharmacogenomic applications beyond oncology into infectious disease, immunology, and vaccine response research has expanded the market's addressable scope. The pandemic also catalyzed investment in genomic data infrastructure globally, creating broader platforms from which pharmacogenomics applications can draw analytical capability and clinical validation evidence.

The Consumables segment is expected to be the largest during the forecast period

The Consumables segment is expected to account for the largest market share during the forecast period, reflecting the recurrent, high-volume purchase of reagents, sequencing kits, genotyping arrays, and sample collection materials required for ongoing genetic testing operations. Unlike instruments, which represent one-time capital expenditures, consumables generate predictable recurring revenue streams that expand in direct proportion to testing volume growth. As pharmacogenomic test volumes increase across reference laboratories, hospital-based testing programs, and direct-to-consumer platforms, consumable demand grows correspondingly. The high-margin consumables model is also favored by instrument manufacturers seeking to build durable, volume-driven revenue streams from their installed testing platform bases.

The Next-Generation Sequencing (NGS) segment is expected to have the highest CAGR during the forecast period

Over the forecast period, the Next-Generation Sequencing (NGS) segment is predicted to witness the highest growth rate, driven by the continuous decline in sequencing costs and the increasing clinical demand for comprehensive multi-gene pharmacogenomic panel analysis. NGS enables simultaneous interrogation of hundreds of pharmacogenomically relevant genetic variants in a single assay, providing superior clinical information density relative to conventional single-gene testing approaches. As NGS becomes cost-competitive with targeted genotyping for panel testing applications, clinical laboratories are increasingly transitioning to sequencing-based pharmacogenomics workflows. Regulatory clearances for NGS-based pharmacogenomic panels are accelerating commercial deployment across oncology and broader therapeutic areas.

Region with largest share:

During the forecast period, the North America region is expected to hold the largest market share, supported by the United States' world-leading precision medicine research infrastructure, progressive regulatory environment, and high density of genomics-oriented pharmaceutical and biotechnology companies. Federal investment through initiatives including the All of Us Research Program is building large-scale pharmacogenomic datasets that underpin clinical evidence generation. The United States also hosts the majority of leading reference laboratories offering comprehensive pharmacogenomic testing services, and clinical guideline bodies including CPIC have created evidence-based prescribing frameworks that are advancing clinical adoption nationally.

Region with highest CAGR:

Over the forecast period, the Asia Pacific region is anticipated to exhibit the highest CAGR, driven by substantial government-funded precision medicine programs in China, Japan, South Korea, and Australia, combined with large genetically diverse populations that provide rich research resources for pharmacogenomic discovery. Domestic genomics industry champions in China are scaling clinical-grade sequencing capabilities rapidly, reducing testing costs and democratizing access to pharmacogenomic insights. Growing awareness among clinicians and patients of genetically guided prescribing benefits, supported by increasing evidence in Asian-specific patient populations, is driving accelerating test volume growth across the region.

Key Players:

Some of the key players in the Pharmacogenomics Market include Thermo Fisher Scientific, Illumina, QIAGEN, F. Hoffmann-La Roche Ltd., Agilent Technologies, Abbott Laboratories, Bio-Rad Laboratories, Danaher Corporation, Myriad Genetics, Eurofins Scientific, Pacific Biosciences, Laboratory Corporation of America Holdings, BD, SOPHiA GENETICS, and Takara Bio Inc.

Key Developments:

In February 2026, Thermo Fisher Scientific unveiled a fully automated pharmacogenomics testing workflow integrating sample-to-report automation with its Ion Torrent sequencing platform, reducing hands-on laboratory technician time and enabling high-throughput clinical pharmacogenomics testing programs to scale efficiently without proportional increases in skilled workforce requirements.

In January 2026, Illumina announced the commercial launch of its expanded pharmacogenomics content panel on the NovaSeq platform, enabling clinical laboratories to deliver comprehensive multi-drug interaction profiling from a single NGS run with enhanced variant classification capabilities, significantly improving turnaround time and clinical decision support quality for pharmacogenomics testing programs.

Products Covered:

  • Instruments
  • Reagents & Consumables
  • Software & Bioinformatics Tools

Technologies Covered:

  • Polymerase Chain Reaction (PCR)
  • DNA Sequencing
  • Microarray
  • Mass Spectrometry
  • Electrophoresis
  • In-Situ Hybridization
  • Other Technologies

Sample Types Covered:

  • Blood Samples
  • Saliva Samples
  • Buccal Swabs
  • Tissue Samples
  • Other Sample Types

Service Types Covered:

  • Pharmacogenomic Testing Services
  • Consulting Services
  • Data Interpretation Services

Applications Covered:

  • Oncology
  • Cardiovascular Diseases
  • Neurology & Psychiatry
  • Infectious Diseases
  • Pain Management
  • Rare Diseases
  • Drug Discovery & Development
  • Personalized Medicine
  • Other Applications

End Users Covered:

  • Hospitals & Clinics
  • Diagnostic Laboratories
  • Academic & Research Institutes
  • Pharmaceutical & Biotechnology Companies
  • Contract Research Organizations (CROs)
  • Other End Users

Regions Covered:

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • United Kingdom
    • Germany
    • France
    • Italy
    • Spain
    • Netherlands
    • Belgium
    • Sweden
    • Switzerland
    • Poland
    • Rest of Europe
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Australia
    • Indonesia
    • Thailand
    • Malaysia
    • Singapore
    • Vietnam
    • Rest of Asia Pacific
  • South America
    • Brazil
    • Argentina
    • Colombia
    • Chile
    • Peru
    • Rest of South America
  • Rest of the World (RoW)
    • Middle East
  • Saudi Arabia
  • United Arab Emirates
  • Qatar
  • Israel
  • Rest of Middle East
    • Africa
  • South Africa
  • Egypt
  • Morocco
  • Rest of Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2023, 2024, 2025, 2026, 2027, 2028, 2030, 3032 and 2034
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

  • 1.1 Market Snapshot and Key Highlights
  • 1.2 Growth Drivers, Challenges, and Opportunities
  • 1.3 Competitive Landscape Overview
  • 1.4 Strategic Insights and Recommendations

2 Research Framework

  • 2.1 Study Objectives and Scope
  • 2.2 Stakeholder Analysis
  • 2.3 Research Assumptions and Limitations
  • 2.4 Research Methodology
    • 2.4.1 Data Collection (Primary and Secondary)
    • 2.4.2 Data Modeling and Estimation Techniques
    • 2.4.3 Data Validation and Triangulation
    • 2.4.4 Analytical and Forecasting Approach

3 Market Dynamics and Trend Analysis

  • 3.1 Market Definition and Structure
  • 3.2 Key Market Drivers
  • 3.3 Market Restraints and Challenges
  • 3.4 Growth Opportunities and Investment Hotspots
  • 3.5 Industry Threats and Risk Assessment
  • 3.6 Technology and Innovation Landscape
  • 3.7 Emerging and High-Growth Markets
  • 3.8 Regulatory and Policy Environment
  • 3.9 Impact of COVID-19 and Recovery Outlook

4 Competitive and Strategic Assessment

  • 4.1 Porter's Five Forces Analysis
    • 4.1.1 Supplier Bargaining Power
    • 4.1.2 Buyer Bargaining Power
    • 4.1.3 Threat of Substitutes
    • 4.1.4 Threat of New Entrants
    • 4.1.5 Competitive Rivalry
  • 4.2 Market Share Analysis of Key Players
  • 4.3 Product Benchmarking and Performance Comparison

5 Global Pharmacogenomics Market, By Product

  • 5.1 Instruments
    • 5.1.1 Sequencing Instruments
    • 5.1.2 PCR Systems
    • 5.1.3 Microarray Systems
    • 5.1.4 Mass Spectrometers
  • 5.2 Reagents & Consumables
    • 5.2.1 Assay Kits
    • 5.2.2 Genotyping Kits
    • 5.2.3 PCR Reagents
    • 5.2.4 Sample Preparation Kits
    • 5.2.5 Sequencing Consumables
  • 5.3 Software & Bioinformatics Tools
    • 5.3.1 Clinical Decision Support Software
    • 5.3.2 Data Analysis Software
    • 5.3.3 Laboratory Information Management Systems (LIMS)

6 Global Pharmacogenomics Market, By Technology

  • 6.1 Polymerase Chain Reaction (PCR)
    • 6.1.1 Standard PCR
    • 6.1.2 Real-Time PCR
    • 6.1.3 Digital PCR
  • 6.2 DNA Sequencing
    • 6.2.1 Next-Generation Sequencing (NGS)
    • 6.2.2 Sanger Sequencing
  • 6.3 Microarray
  • 6.4 Mass Spectrometry
  • 6.5 Electrophoresis
  • 6.6 In-Situ Hybridization
  • 6.7 Other Technologies

7 Global Pharmacogenomics Market, By Sample Type

  • 7.1 Blood Samples
  • 7.2 Saliva Samples
  • 7.3 Buccal Swabs
  • 7.4 Tissue Samples
  • 7.5 Other Sample Types

8 Global Pharmacogenomics Market, By Service Type

  • 8.1 Pharmacogenomic Testing Services
  • 8.2 Consulting Services
  • 8.3 Data Interpretation Services

9 Global Pharmacogenomics Market, By Application

  • 9.1 Oncology
  • 9.2 Cardiovascular Diseases
  • 9.3 Neurology & Psychiatry
  • 9.4 Infectious Diseases
  • 9.5 Pain Management
  • 9.6 Rare Diseases
  • 9.7 Drug Discovery & Development
  • 9.8 Personalized Medicine
  • 9.9 Other Applications

10 Global Pharmacogenomics Market, By End User

  • 10.1 Hospitals & Clinics
  • 10.2 Diagnostic Laboratories
  • 10.3 Academic & Research Institutes
  • 10.4 Pharmaceutical & Biotechnology Companies
  • 10.5 Contract Research Organizations (CROs)
  • 10.6 Other End Users

11 Global Pharmacogenomics Market, By Geography

  • 11.1 North America
    • 11.1.1 United States
    • 11.1.2 Canada
    • 11.1.3 Mexico
  • 11.2 Europe
    • 11.2.1 United Kingdom
    • 11.2.2 Germany
    • 11.2.3 France
    • 11.2.4 Italy
    • 11.2.5 Spain
    • 11.2.6 Netherlands
    • 11.2.7 Belgium
    • 11.2.8 Sweden
    • 11.2.9 Switzerland
    • 11.2.10 Poland
    • 11.2.11 Rest of Europe
  • 11.3 Asia Pacific
    • 11.3.1 China
    • 11.3.2 Japan
    • 11.3.3 India
    • 11.3.4 South Korea
    • 11.3.5 Australia
    • 11.3.6 Indonesia
    • 11.3.7 Thailand
    • 11.3.8 Malaysia
    • 11.3.9 Singapore
    • 11.3.10 Vietnam
    • 11.3.11 Rest of Asia Pacific
  • 11.4 South America
    • 11.4.1 Brazil
    • 11.4.2 Argentina
    • 11.4.3 Colombia
    • 11.4.4 Chile
    • 11.4.5 Peru
    • 11.4.6 Rest of South America
  • 11.5 Rest of the World (RoW)
    • 11.5.1 Middle East
      • 11.5.1.1 Saudi Arabia
      • 11.5.1.2 United Arab Emirates
      • 11.5.1.3 Qatar
      • 11.5.1.4 Israel
      • 11.5.1.5 Rest of Middle East
    • 11.5.2 Africa
      • 11.5.2.1 South Africa
      • 11.5.2.2 Egypt
      • 11.5.2.3 Morocco
      • 11.5.2.4 Rest of Africa

12 Strategic Market Intelligence

  • 12.1 Industry Value Network and Supply Chain Assessment
  • 12.2 White-Space and Opportunity Mapping
  • 12.3 Product Evolution and Market Life Cycle Analysis
  • 12.4 Channel, Distributor, and Go-to-Market Assessment

13 Industry Developments and Strategic Initiatives

  • 13.1 Mergers and Acquisitions
  • 13.2 Partnerships, Alliances, and Joint Ventures
  • 13.3 New Product Launches and Certifications
  • 13.4 Capacity Expansion and Investments
  • 13.5 Other Strategic Initiatives

14 Company Profiles

  • 14.1 Thermo Fisher Scientific
  • 14.2 Illumina
  • 14.3 QIAGEN
  • 14.4 F. Hoffmann-La Roche Ltd.
  • 14.5 Agilent Technologies
  • 14.6 Abbott Laboratories
  • 14.7 Bio-Rad Laboratories
  • 14.8 Danaher Corporation
  • 14.9 Myriad Genetics
  • 14.10 Eurofins Scientific
  • 14.11 Pacific Biosciences
  • 14.12 Laboratory Corporation of America Holdings
  • 14.13 BD
  • 14.14 SOPHiA GENETICS
  • 14.15 Takara Bio Inc.

List of Tables

  • Table 1 Global Pharmacogenomics Market Outlook, By Region (2023-2034) ($MN)
  • Table 2 Global Pharmacogenomics Market Outlook, By Product (2023-2034) ($MN)
  • Table 3 Global Pharmacogenomics Market Outlook, By Instruments (2023-2034) ($MN)
  • Table 4 Global Pharmacogenomics Market Outlook, By Sequencing Instruments (2023-2034) ($MN)
  • Table 5 Global Pharmacogenomics Market Outlook, By PCR Systems (2023-2034) ($MN)
  • Table 6 Global Pharmacogenomics Market Outlook, By Microarray Systems (2023-2034) ($MN)
  • Table 7 Global Pharmacogenomics Market Outlook, By Mass Spectrometers (2023-2034) ($MN)
  • Table 8 Global Pharmacogenomics Market Outlook, By Reagents & Consumables (2023-2034) ($MN)
  • Table 9 Global Pharmacogenomics Market Outlook, By Assay Kits (2023-2034) ($MN)
  • Table 10 Global Pharmacogenomics Market Outlook, By Genotyping Kits (2023-2034) ($MN)
  • Table 11 Global Pharmacogenomics Market Outlook, By PCR Reagents (2023-2034) ($MN)
  • Table 12 Global Pharmacogenomics Market Outlook, By Sample Preparation Kits (2023-2034) ($MN)
  • Table 13 Global Pharmacogenomics Market Outlook, By Sequencing Consumables (2023-2034) ($MN)
  • Table 14 Global Pharmacogenomics Market Outlook, By Software & Bioinformatics Tools (2023-2034) ($MN)
  • Table 15 Global Pharmacogenomics Market Outlook, By Clinical Decision Support Software (2023-2034) ($MN)
  • Table 16 Global Pharmacogenomics Market Outlook, By Data Analysis Software (2023-2034) ($MN)
  • Table 17 Global Pharmacogenomics Market Outlook, By Laboratory Information Management Systems (LIMS) (2023-2034) ($MN)
  • Table 18 Global Pharmacogenomics Market Outlook, By Technology (2023-2034) ($MN)
  • Table 19 Global Pharmacogenomics Market Outlook, By Polymerase Chain Reaction (PCR) (2023-2034) ($MN)
  • Table 20 Global Pharmacogenomics Market Outlook, By Standard PCR (2023-2034) ($MN)
  • Table 21 Global Pharmacogenomics Market Outlook, By Real-Time PCR (2023-2034) ($MN)
  • Table 22 Global Pharmacogenomics Market Outlook, By Digital PCR (2023-2034) ($MN)
  • Table 23 Global Pharmacogenomics Market Outlook, By DNA Sequencing (2023-2034) ($MN)
  • Table 24 Global Pharmacogenomics Market Outlook, By Next-Generation Sequencing (NGS) (2023-2034) ($MN)
  • Table 25 Global Pharmacogenomics Market Outlook, By Sanger Sequencing (2023-2034) ($MN)
  • Table 26 Global Pharmacogenomics Market Outlook, By Microarray (2023-2034) ($MN)
  • Table 27 Global Pharmacogenomics Market Outlook, By Mass Spectrometry (2023-2034) ($MN)
  • Table 28 Global Pharmacogenomics Market Outlook, By Electrophoresis (2023-2034) ($MN)
  • Table 29 Global Pharmacogenomics Market Outlook, By In-Situ Hybridization (2023-2034) ($MN)
  • Table 30 Global Pharmacogenomics Market Outlook, By Other Technologies (2023-2034) ($MN)
  • Table 31 Global Pharmacogenomics Market Outlook, By Sample Type (2023-2034) ($MN)
  • Table 32 Global Pharmacogenomics Market Outlook, By Blood Samples (2023-2034) ($MN)
  • Table 33 Global Pharmacogenomics Market Outlook, By Saliva Samples (2023-2034) ($MN)
  • Table 34 Global Pharmacogenomics Market Outlook, By Buccal Swabs (2023-2034) ($MN)
  • Table 35 Global Pharmacogenomics Market Outlook, By Tissue Samples (2023-2034) ($MN)
  • Table 36 Global Pharmacogenomics Market Outlook, By Other Sample Types (2023-2034) ($MN)
  • Table 37 Global Pharmacogenomics Market Outlook, By Service Type (2023-2034) ($MN)
  • Table 38 Global Pharmacogenomics Market Outlook, By Pharmacogenomic Testing Services (2023-2034) ($MN)
  • Table 39 Global Pharmacogenomics Market Outlook, By Consulting Services (2023-2034) ($MN)
  • Table 40 Global Pharmacogenomics Market Outlook, By Data Interpretation Services (2023-2034) ($MN)
  • Table 41 Global Pharmacogenomics Market Outlook, By Application (2023-2034) ($MN)
  • Table 42 Global Pharmacogenomics Market Outlook, By Oncology (2023-2034) ($MN)
  • Table 43 Global Pharmacogenomics Market Outlook, By Cardiovascular Diseases (2023-2034) ($MN)
  • Table 44 Global Pharmacogenomics Market Outlook, By Neurology & Psychiatry (2023-2034) ($MN)
  • Table 45 Global Pharmacogenomics Market Outlook, By Infectious Diseases (2023-2034) ($MN)
  • Table 46 Global Pharmacogenomics Market Outlook, By Pain Management (2023-2034) ($MN)
  • Table 47 Global Pharmacogenomics Market Outlook, By Rare Diseases (2023-2034) ($MN)
  • Table 48 Global Pharmacogenomics Market Outlook, By Drug Discovery & Development (2023-2034) ($MN)
  • Table 49 Global Pharmacogenomics Market Outlook, By Personalized Medicine (2023-2034) ($MN)
  • Table 50 Global Pharmacogenomics Market Outlook, By Other Applications (2023-2034) ($MN)
  • Table 51 Global Pharmacogenomics Market Outlook, By End User (2023-2034) ($MN)
  • Table 52 Global Pharmacogenomics Market Outlook, By Hospitals & Clinics (2023-2034) ($MN)
  • Table 53 Global Pharmacogenomics Market Outlook, By Diagnostic Laboratories (2023-2034) ($MN)
  • Table 54 Global Pharmacogenomics Market Outlook, By Academic & Research Institutes (2023-2034) ($MN)
  • Table 55 Global Pharmacogenomics Market Outlook, By Pharmaceutical & Biotechnology Companies (2023-2034) ($MN)
  • Table 56 Global Pharmacogenomics Market Outlook, By Contract Research Organizations (CROs) (2023-2034) ($MN)
  • Table 57 Global Pharmacogenomics Market Outlook, By Other End Users (2023-2034) ($MN)

Note: Tables for North America, Europe, APAC, South America, and Rest of the World (RoW) are also represented in the same manner as above.